Alligator's mitazalimab shown to enhance cancer vaccine

By Pr Newswire7 days ago

LUND, Sweden, May 5, 2021 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.

The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine.


Title:The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells and enhances anti-tumor efficacy of a model cancer vaccine in vivo

Journal:Cancer Immunology, Immunotherapy

Continue read on